Earnings summaries and quarterly performance for Celularity.
Executive leadership at Celularity.
Board of directors at Celularity.
Research analysts covering Celularity.
Recent press releases and 8-K filings for CELU.
Celularity Receives $12.2 Million from Sale of New Jersey NOLs and R&D Tax Credits
CELU
New Projects/Investments
- Celularity Inc. received $12.2 Million in net cash proceeds from the sale of its unused New Jersey net operating losses (NOLs) and research and development (R&D) tax credits.
- The sale involved approximately $126.3 Million of NOLs and $1.9 Million of R&D tax credits, administered through New Jersey’s Technology Business Tax Certificate Transfer Program.
- These funds provide non-dilutive, tax-free capital, strengthening the company's balance sheet and enhancing liquidity.
- The capital will support disciplined allocation to commercial opportunities for Celularity's stem cell and regenerative medicine programs.
Feb 10, 2026, 1:30 PM
Celularity Comments on CMS Withdrawal of Skin Substitute Coverage Determinations
CELU
- The Centers for Medicare & Medicaid Services (CMS) withdrew Local Coverage Determinations (LCDs) for skin substitute grafts, which were set to take effect on January 1, 2026. These LCDs would have eliminated Medicare coverage for 158 skin substitute products from other companies, but Celularity's Biovance® and Biovance 3L remained eligible.
- Despite the LCD withdrawal, CMS's new payment policy, effective January 1, 2026, will pay a flat rate of $127.28 per square centimeter for all skin substitute applications furnished in physician office and hospital outpatient settings.
- Celularity's CEO, Robert J. Hariri, stated that the company's Biovance® manufacturing process is efficient and scalable, enabling them to operate comfortably under the new Medicare reimbursement policy. He also highlighted real-world evidence supporting Biovance®'s effectiveness in treating chronic wounds.
Dec 26, 2025, 1:30 PM
Celularity Closes Financing Transactions
CELU
Debt Issuance
New Projects/Investments
- Celularity Inc. announced the closing of financing transactions on December 22, 2025, securing $10.00 million in gross proceeds.
- The financing package includes a $7.0 million senior secured term loan and secured convertible notes with aggregate commitments up to $5.0 million, convertible into Class A common stock at $1.66 per share.
- The company also issued five-year warrants to purchase 3,707,657 shares of Class A Common Stock, exercisable from June 19, 2026, at an exercise price of $2.00 per share.
- There is potential for an additional $2.0 million in funding, contingent on specific closing conditions and the investor's election.
- These funds are intended to bolster Celularity's financial position and support its ongoing operations and strategic initiatives, particularly in leveraging its placental-derived platform for healthy aging and performance optimization.
Dec 23, 2025, 9:15 PM
Celularity Closes Financing Transactions
CELU
Debt Issuance
Convertible Preferred Issuance
New Projects/Investments
- Celularity Inc. announced the closing of financing transactions with Philip A. Barach, receiving $10.00 million in gross proceeds.
- The financing package includes a $7.0 million senior secured term loan and secured convertible notes with aggregate commitments of up to $5.0 million, convertible into Class A common stock at $1.66 per share.
- Additionally, Celularity issued five-year warrants to purchase 3,707,657 shares of Class A Common Stock, exercisable from June 19, 2026, at $2.00 per share.
- These funds are intended to support Celularity\u2019s ongoing operations and strategic initiatives, with a focus on leveraging its placental-derived platform to address healthy aging, performance optimization, longevity, and age-related disease.
Dec 22, 2025, 9:01 PM
Celularity Inc. Authorizes Issuance of Series A Convertible Preferred Stock
CELU
Convertible Preferred Issuance
- Celularity Inc. (CELU) authorized the issuance of 6,000,000 shares of Series A Convertible Preferred Stock via unanimous written consent on October 24, 2025.
- The company will issue up to $6,666,667 in stated value of Series A Convertible Preferred Stock, with each share having a stated value of $1.111111 and purchased at 90% of its stated value.
- The Series A Convertible Preferred Stock carries a dividend rate of 5.0% per annum, which increases to 18.0% per annum during a Triggering Event, and has a maturity date of twelve months after its initial issuance.
- Key conversion terms include a Floor Price of $1.60 per share and a Beneficial Ownership Limitation of 4.99% of the outstanding Common Stock.
Oct 28, 2025, 1:29 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more